Cyclo Therapeutics (CYTH) Competitors $0.72 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYTH vs. SLS, CCCC, BHST, OPTN, TIL, COYA, ORMP, IMUX, CLYM, and CRVOShould you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include SELLAS Life Sciences Group (SLS), C4 Therapeutics (CCCC), BioHarvest Sciences (BHST), OptiNose (OPTN), Instil Bio (TIL), Coya Therapeutics (COYA), Oramed Pharmaceuticals (ORMP), Immunic (IMUX), Climb Bio (CLYM), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. Cyclo Therapeutics vs. SELLAS Life Sciences Group C4 Therapeutics BioHarvest Sciences OptiNose Instil Bio Coya Therapeutics Oramed Pharmaceuticals Immunic Climb Bio CervoMed SELLAS Life Sciences Group (NASDAQ:SLS) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Do insiders and institutionals have more ownership in SLS or CYTH? 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are held by institutional investors. 1.2% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is SLS or CYTH more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Cyclo Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -629.46% -178.65% Cyclo Therapeutics -2,847.19%N/A -307.16% Which has more volatility and risk, SLS or CYTH? SELLAS Life Sciences Group has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.57, suggesting that its share price is 157% less volatile than the S&P 500. Does the MarketBeat Community favor SLS or CYTH? SELLAS Life Sciences Group and Cyclo Therapeutics both received 10 outperform votes by MarketBeat users. However, 71.43% of users gave Cyclo Therapeutics an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformSELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Cyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Do analysts recommend SLS or CYTH? Cyclo Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 31.83%. Given Cyclo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cyclo Therapeutics is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger earnings & valuation, SLS or CYTH? Cyclo Therapeutics has lower revenue, but higher earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M118.10-$37.34M-$0.52-2.50Cyclo Therapeutics$870.73K27.24-$20.06M-$0.90-0.80 Does the media favor SLS or CYTH? In the previous week, SELLAS Life Sciences Group's average media sentiment score of 0.00 equaled Cyclo Therapeutics'average media sentiment score. Company Overall Sentiment SELLAS Life Sciences Group Neutral Cyclo Therapeutics Neutral SummaryCyclo Therapeutics beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks. Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTH vs. The Competition Export to ExcelMetricCyclo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.72M$2.84B$5.29B$7.35BDividend YieldN/A1.87%5.12%4.31%P/E Ratio-0.8030.4821.7317.77Price / Sales27.24441.91379.1697.65Price / CashN/A168.6838.2234.64Price / Book3.433.466.443.98Net Income-$20.06M-$72.06M$3.21B$247.44M7 Day PerformanceN/A2.52%2.81%1.82%1 Month Performance10.86%-15.73%-8.67%-6.98%1 Year Performance-39.95%-26.11%11.32%1.49% Cyclo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTHCyclo Therapeutics2.7763 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809SLSSELLAS Life Sciences Group0.1639 of 5 stars$1.04flatN/A-7.8%$94.48M$1M-1.5110CCCCC4 Therapeutics2.4682 of 5 stars$1.33+1.5%$12.50+839.8%-81.8%$94.42M$35.58M-0.78150News CoverageBHSTBioHarvest SciencesN/A$5.60+1.1%$13.00+132.1%N/A$91.98M$25.19M-4.48N/APositive NewsOPTNOptiNose3.2922 of 5 stars$9.10flat$9.00-1.1%-40.1%$91.66M$78.23M-2.17190Short Interest ↓Positive NewsHigh Trading VolumeTILInstil Bio2.0767 of 5 stars$13.88-5.0%$114.00+721.3%+45.9%$90.58MN/A-1.20410COYACoya Therapeutics2.427 of 5 stars$5.39-1.1%$17.00+215.4%-36.2%$90.15M$3.55M-8.296Positive NewsGap UpORMPOramed Pharmaceuticals1.4808 of 5 stars$2.10flatN/A-7.7%$85.79M$1.34M19.0910Gap DownIMUXImmunic2.7898 of 5 stars$0.94-5.2%$13.20+1,299.5%-19.0%$85.03MN/A-0.7770Analyst ForecastAnalyst RevisionNews CoverageCLYMClimb Bio2.4449 of 5 stars$1.26+7.7%$10.00+693.7%N/A$85.02MN/A-0.599Gap DownCRVOCervoMed3.5888 of 5 stars$9.76-11.9%$27.50+181.8%-60.8%$84.94M$7.14M-4.814Short Interest ↓Gap Up Related Companies and Tools Related Companies SLS Alternatives CCCC Alternatives BHST Alternatives OPTN Alternatives TIL Alternatives COYA Alternatives ORMP Alternatives IMUX Alternatives CLYM Alternatives CRVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTH) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTH Stock Free CYTH Stock Alerts